Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.

Latest News

  • 15 Sep
    2020

    Results for the year ended 30 June 2020

    Successful commercialisation of Alkindi® underpins development of European commercial b

    Read More

  • 03 Sep
    2020

    Diurnal signs two further marketing and distribution agreements for the Benelux Union and Switzerland

    Advances Company’s strategy of partnering outside key European territories

    Read More

  • 27 Aug
    2020

    Professor Richard Ross receives international honour from Endocrine Society

    Professor Richard Ross, a founding Director of Diurnal and Chief Scientific Officer, has been recognised by the Endocrine Society’s 2021 Laureate Awards for Outstanding Innovation.

    Read More